Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 50%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc. exhibits a compelling growth trajectory, bolstered by its ability to cross-sell services and expand high-revenue contracts, notably forecasting potential growth from the Aetna contract to over $2 billion in annual revenue. The company reported strong top-line growth, exceeding its mid-teens revenue growth target, while maintaining a robust pipeline valued at $650 million, signaling significant market demand for its specialty-focused value-based care solutions. Evolent's strategic positioning leverages ongoing shifts in government programs towards value-based payment models, enhancing its prospects in the evolving healthcare landscape.

Bears say

The analysis of Evolent Health's financial outlook reveals significant concerns regarding projected revenue and EBITDA declines. The company anticipates a decrease in non-enhanced revenue from approximately $285 million in 2025 to $170 million in 2026, exacerbated by expected declines in Exchange and Medicare Advantage contracts. Additionally, potential drops in Medicaid membership and higher-margin Exchange enrollment could result in EBITDA reductions of $8 million to $15 million or more, reflecting a challenging environment for revenue stability and profitability.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 50% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.